Investigating neurological disorders in people living with HIV
Official title: Neurological Disorders in HIV-1 Infection
Funded at University of Nebraska Medical Center · NIH-11008730 · Data updated 2026-11-12
This study is looking at how a substance related to sugar breakdown might affect brain health in middle-aged people with HIV, using mice to see if lowering this substance can help improve their symptoms.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project start | August 15, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $230,250 |
| NIH project number | 1R21NS139920-01 |
| Project ID | NIH-11008730 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are middle-aged individuals living with HIV who are experiencing neurological symptoms.
✕Less likely to help
Patients who are not living with HIV or who do not exhibit neurological symptoms may not benefit from this research.
What this research studies
This research focuses on understanding the neurological disorders associated with HIV infection, particularly in middle-aged individuals. It aims to explore the role of a glycolytic byproduct called methylglyoxal in triggering these disorders by examining its effects on different brain cell types. The study will utilize a mouse model to investigate the relationship between methylglyoxal levels, inflammation, and neurological function, as well as test new treatments using cyclic peptides to reduce methylglyoxal and potentially alleviate symptoms.
Why it matters
Potential benefit: If successful, this research could lead to new treatments for neurological disorders in people living with HIV.
How similar studies have gone: While the specific approach of targeting methylglyoxal in this context is novel, related research has shown promise in understanding and treating neurological disorders in HIV-infected populations.
Where this research is happening
-
University of Nebraska Medical Center
Omaha, United States Active
Researchers
- Principal investigator: Bidasee, Keshore R — University of Nebraska Medical Center
- Study coordinator: Bidasee, Keshore R
Related research
Other NIH-funded projects on the same topics.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Phosphatidylserine-targeting antibodies and T cell function in HIV-1 infection
This NIH grant will explore how antibodies that target phosphatidylserine affect immune cells in people living with HIV on ART.
-
Ribosomal frameshifting in HIV-1 infection and its effects on inflammation and brain health
A study at the University of Rochester will explore how HIV-1 may change human cell machinery to boost its own replication and cause inflammation and brain-related problems.
-
Targeting NLRP3 inflammasome to protect HIV patients from stroke
A small NIH grant will explore whether HIV infection makes stroke worse and whether blocking a brain inflammation pathway (NLRP3) could protect brain tissue.
-
Reprogramming tissue immune cells (macrophages) to target hidden HIV
Trying small drug molecules to reprogram tissue immune cells so infected cells die and hidden HIV is reduced in people living with HIV.
-
EHD4 protein and HIV-1 infection: a new potential antiviral target
A study to understand how the human protein EHD4 affects HIV-1 infection and whether it could be targeted to develop better antiviral therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.